Compare NCA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCA | PGEN |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.3M | 1.5B |
| IPO Year | N/A | N/A |
| Metric | NCA | PGEN |
|---|---|---|
| Price | $8.80 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 59.6K | ★ 4.2M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $7.77 | $0.65 |
| 52 Week High | $9.12 | $5.23 |
| Indicator | NCA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.84 | 48.12 |
| Support Level | $8.77 | $3.42 |
| Resistance Level | $8.94 | $3.75 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 5.26 | 50.00 |
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.